AstraZeneca is presenting a broad package of new clinical and real-world data for Saphnelo (anifrolumab) at EULAR 2026, reinforcing its long-term efficacy profile in systemic lupus erythematosus (SLE), with a focus on sustained remission, glucocorticoid (GC) reduction and potential organ protection.

The data spans post-hoc analyses, long-term extensions and observational studies, collectively aimed at strengthening the case for anifrolumab as a disease-modifying therapy in a condition where durable remission remains difficult to achieve.

Systemic lupus erythematosus affects an estimated 3.4 million people worldwide, yet fewer than 10% of patients are currently able to achieve remission, according to estimates cited by the company. The disease is characterised by chronic inflammation affecting multiple organ systems and is often managed with long-term immunosuppression, including corticosteroids.

Among the key datasets being presented is ASTER, which evaluates sustained remission over a 12-month period. AstraZeneca said the findings show higher rates of DORIS-defined remission alongside a lower incidence of serious adverse events compared with earlier clinical trial reports.

The LASER extension study provides up to four years of follow-up data, which the company said supports a sustained organ-protective effect and reinforces the long-term use of anifrolumab in patients with SLE.

Additional analyses from the TULIP-SC programme suggest that anifrolumab may support broader disease control across multiple organ systems, while also reducing dependence on glucocorticoids and improving quality of life measures. These findings are based on post-hoc analyses of clinical trial data.

Real-world evidence is also being presented at EULAR 2026. The MAGNOLIA observational study, which links claims and laboratory data, suggests improvements in renal, hematologic and immunologic parameters following initiation of anifrolumab in treated patients.

Similarly, the AZAHAR study, conducted across 20 centres in Spain, reports reductions in disease activity and flare frequency in routine clinical practice, alongside achievement of clinical remission at 6 and 12 months. The company said these findings support the role of anifrolumab in treat-to-target strategies for SLE.

Further data from AZALEA and LILAC highlight reductions in glucocorticoid use in Asian patient populations, contributing to the broader evidence base in historically underrepresented groups.

While the dataset package spans multiple study designs, including observational and post-hoc analyses, the overall direction is consistent: sustained disease control, reduced steroid burden and longer-term management of SLE.

However, most of the new analyses are not head-to-head comparative studies, and the findings are not designed to demonstrate superiority over other biologic therapies in SLE. Instead, they add to an evolving evidence base supporting long-term use of anifrolumab in routine care settings.

AstraZeneca said the data reinforce its goal of moving SLE treatment beyond short-term symptom control towards durable remission and improved long-term outcomes for patients.